摘要
目的探讨^(99m)Tc-联肼尼克酰胺-3聚乙二醇-精氨酸-甘氨酸-天冬氨酸环肽二聚体(^(99m)Tc-3PRGD2)整合素受体显像与乳腺癌分子分型及病理相关性。方法回顾分析61例乳腺癌患者的^(99m)Tc-3PRGD2整合素受体SPECT/CT显像T/N比值与最大标准化摄取值(SUVmax)乳腺与术后病理及ER、PR、HER2、Ki67表达情况。结果 HER2阳性和淋巴结浸润状态与高T/N比值及高SUVmax相关,P<0.05。ER、PR及Ki67的表达状态与T/N比值及SUVmax无相关。结论通过^(99m)Tc-3PRGD2 SPECT/CT显像评价T/N比值和SUVmax可能有助于发现HER2亚型及淋巴结侵袭,并为治疗方案选择提供重要信息。
Objective To investigate -（99m）Tc-3 PRGD2 S PECT/CT integrin receptor imaging and breast cancer molecular classification and pathologic correlation. Methods The expression of -（99m）Tc-3 PRGD2 integrin receptor SPECT/CT imaging T/N ratio in 61 breast cancer patients and SUVmax breast and postoperative pathology, ER, PR, HER2 and Ki67 were retrospectively analyzed. Results HER2 positive and lymph node infiltration status were significantly correlated with high T/N ratio and high SUVmax, P〈0.05. The expression status of ER, PR and Ki67 was not significantly correlated with T/N ratio and SUVmax. Conclusion Using -（99m）Tc-3 PRGD2 SPECT/CT imaging to evaluate T/N ratio and SUVmax may help to find HER2 subtype and lymph node invasion, and provide important information for treatment options selection.
作者
欧阳忠
陈贵兵
OUYANG Zhong1, CHEN Guibing2(1. Deprtment of Breast Surgery, The First Affiliated Hospital of Xiamen University, Xiamen Fujian 361003, China; 2. Department of Nuclear Medicin)
出处
《中国卫生标准管理》
2018年第18期124-126,共3页
China Health Standard Management
基金
福建省厦门市卫生局资助2013年福建省科技计划项目(2013D019)
